When president-elect Donald Trump announced that he would nominate Robert F Kennedy Jr to be his secretary of Health and ...
The U.S. patient population for Revuforj in its approved indication is roughly 2,000 according to Syndax. KMT2A leukemias ...
Critics say that, if RFK Jr. is made secretary of the HHS, a radical antiestablishment medical movement with roots in past centuries would take power.
BTIG analyst Justin Zelin has reiterated their bullish stance on SNDX stock, giving a Buy rating on November 15.Don't Miss our Black Friday ...
In another sign of biopharma's waning interest in the traditional ex vivo gene therapy approach, CSL Behring is shutti | CSL ...
US stock futures traded in a mixed fashion Monday, with traders awaiting more corporate earnings as well as speeches from a number of Fed officials. Here are some of the biggest premarket US stock ...
The US Food and Drug Administration (FDA) has approved Syndax Pharmaceuticals' Revuforj (revumenib) for treating relapsed or ...
Moberg Pharma's MOB-015 has outstanding clinical trial data, 76% cure rate, double the current standard topical, Jublia. Read ...
AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically ...
Continuous glucose monitors, or CGMs, have become more accessible since the Food and Drug Administration cleared them for ...
President-elect Trump’s decision to nominate Robert F. Kennedy Jr. for Health and Human Services (HHS) secretary will put some of the former independent presidential candidate’s most ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback